Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.45 |
| ▸ | PKLR | P30613 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352520 | 0.86 | PKM (0.43) | PKMPKLRGAASMN1; SMN2 | |
| SCHEMBL15353121 | 0.86 | PKM (0.39) | PKMPKLRHTR6GAAMAPK1 | |
| SCHEMBL8854502 | 0.80 | KCNN4 (0.36) | PKMPKLRHTR6PTGES2SLC40A1 | |
| SCHEMBL16467704 | 0.77 | AGTR1 (0.34) | PKMPTGES2CES2CES1 | |
| SCHEMBL16467626 | 0.77 | PKM (0.45) | PKMPKLRHTR6PTGES2CES2 | |
| SCHEMBL14114762 | 0.77 | PKM (0.41) | PKMPKLRHTR6CES2CES1 | |
| SCHEMBL6115202 | 0.76 | PKM (0.44) | PKMPKLRHTR6CES2CES1 | |
| SCHEMBL8761324 | 0.76 | KMT2A (0.45) | HTR6KMT2ASMN1; SMN2KAT6A | |
| SCHEMBL15353308 | 0.75 | MAPT (0.38) | KMT2ASMN1; SMN2CES1KEAP1 | |
| SCHEMBL15352172 | 0.74 | CCR4 (0.46) | HTR6GAAMAPK1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110635167-B | Nonaqueous electrolyte solution, battery containing same, and electric vehicle | 比亚迪股份有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-110635167-A | Nonaqueous electrolyte solution, battery containing same, and electric vehicle | 比亚迪股份有限公司 | 2019-12-31 | — | — | CN | claimed |
| CN-110635167-B | Nonaqueous electrolyte solution, battery containing same, and electric vehicle | 比亚迪股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| CN-110635167-A | Nonaqueous electrolyte solution, battery containing same, and electric vehicle | 比亚迪股份有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | PKM 1646/4885PKLR 2338/4885HTR6 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.